一个口服工程-复合微球抑制炎症性肠道疾病和逆转慢性纤维化
Wenyu Qiao1,2, Luling Yang3, Yu Liu4
1Center of Emergency & Intensive Care Unit, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Journal of nanobiotechnology
|December 30, 2025
概括
这项研究开发了新的微球,它们结合了抗氧化和抗炎性质,用于治疗炎症性肠病 (IBD). 该疗法在动物模型中有效降低了疾病活性和纤维化,为IBD管理提供了一种新方法.
科学领域:
- 生物材料科学 生物材料科学
- 胃肠病学 胃肠病学
- 纳米技术纳米技术
背景情况:
- 炎症性肠病 (IBD) 的发病包括反应性氧物种 (ROS) 和肠道失调.
- 纤维化是IBD的一个重要并发症,导致严重的组织损伤.
- 目前对IBD和相关纤维化的治疗有局限性.
研究的目的:
- 开发一种多功能治疗微球系统,用于在IBD中产生协同作用的抗氧化,抗炎和抗纤维作用.
- 用于封装装载有TGF-β/Smad路径抑制剂的空心中等氧化纳米粒子 (HCeO2).
- 在临床前IBD模型中评估复合制剂 (KP1@HCeO2@SAM) 的疗效.
主要方法:
- 使用微流体方法制造多功能治疗微球.
- 用KP1抑制剂封装空洞的半孔氧化物纳米颗粒 (HCeO2).
- 评估微球的特性,包括ROS清除,微生物群调节和抗纤维活性.
- 在硫酸 (DSS) 诱导的小鼠结肠炎模型中的体内评估.
主要成果:
- 微球显示了长时间的肠保持和调节的肠道微生物群,增加了益生菌7倍.
- 实现了>95%的ROS清除效率和显著抑制纤维化信号传递.
- 在DSS诱导的大肠炎中,治疗降低了疾病活动指数 (DAI) >76%并恢复了肠道屏障完整性>90%.
- 在α-SMA表达下降66%,表明纤维化进展的缓解.
结论:
- 开发的KP1@HCeO2@SAM微球为IBD提供了一个新的,整合性的治疗平台.
- 该系统有效地解决了关键的病理机制,包括氧化应激,炎症和纤维化.
- 这种方法显示出对炎症性肠病及其并发症的治疗有很大的潜力.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
447
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
447
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
435
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
435
Drugs for Treatment of Ulcerative Colitis in IBD
413
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
413
Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
402
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
402
Drugs for Treatment of Constipation-Predominant IBS
664
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
664


